CN101730711B - 降钙素原前体抗原t表位 - Google Patents

降钙素原前体抗原t表位 Download PDF

Info

Publication number
CN101730711B
CN101730711B CN200880021020XA CN200880021020A CN101730711B CN 101730711 B CN101730711 B CN 101730711B CN 200880021020X A CN200880021020X A CN 200880021020XA CN 200880021020 A CN200880021020 A CN 200880021020A CN 101730711 B CN101730711 B CN 101730711B
Authority
CN
China
Prior art keywords
peptide
seq
cells
polynucleotide
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880021020XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101730711A (zh
Inventor
法腾·埃拉阿热
文森特·施特罗班特
皮埃尔·G·库利耶
法蒂埃·马米-舒艾卜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medical Research
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
French National Institute Of Health And Medical Research
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medical Research, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical French National Institute Of Health And Medical Research
Publication of CN101730711A publication Critical patent/CN101730711A/zh
Application granted granted Critical
Publication of CN101730711B publication Critical patent/CN101730711B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880021020XA 2007-06-22 2008-06-19 降钙素原前体抗原t表位 Active CN101730711B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290777.7 2007-06-22
EP07290777A EP2006384A1 (en) 2007-06-22 2007-06-22 Preprocalcitonin-derived antigen epitopes
PCT/IB2008/002625 WO2009010874A2 (en) 2007-06-22 2008-06-19 Preprocalcitonin antigen t epitopes

Publications (2)

Publication Number Publication Date
CN101730711A CN101730711A (zh) 2010-06-09
CN101730711B true CN101730711B (zh) 2013-05-01

Family

ID=38676532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880021020XA Active CN101730711B (zh) 2007-06-22 2008-06-19 降钙素原前体抗原t表位

Country Status (10)

Country Link
US (1) US8492342B2 (enExample)
EP (2) EP2006384A1 (enExample)
JP (1) JP5393661B2 (enExample)
CN (1) CN101730711B (enExample)
AT (1) ATE539087T1 (enExample)
AU (1) AU2008277350B2 (enExample)
CA (1) CA2691406C (enExample)
DK (1) DK2170941T3 (enExample)
ES (1) ES2379209T3 (enExample)
WO (1) WO2009010874A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3115058A1 (fr) 2015-07-09 2017-01-11 Institut Gustave Roussy Peptides immunogenes de preprocalcitonine
CN106110305B (zh) * 2016-08-03 2018-07-17 黑龙江中医药大学 包含升麻皂苷的药物制剂及其应用
CN105999232B (zh) * 2016-08-03 2018-07-03 黑龙江中医药大学 包含升麻皂苷的药物组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075179A2 (en) * 2000-03-31 2001-10-11 Ludwig Institute For Cancer Research Preprocalcitonin as tumor rejection antigen precursor and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F EL HAGE ET AL..Preprocalcitonin signal peptide generates a cytotoxic t lymphocyyte-defined tumor epitope processed by a proteasone-independent pathway.《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA》.2008,第105卷(第29期),第10119-10124页. *
J M LE MOULLEC ET AL..The complete sequence of human preprocalcitonin.《FEBS LETTERS》.1984,第167卷(第1期),第93-97页. *
S MINVIELLE ET AL..A novel calcitonin carboxyl-terminal peptide produced in medullary thyroid carcinoma by alternative RNA processing of the calcitonin/calcitonin gene-related protein.《JOURNAL OF BIOLOGICAL CHEMISTRY》.1991,第266卷(第36期),第24627-24631页. *

Also Published As

Publication number Publication date
JP2010530748A (ja) 2010-09-16
WO2009010874A2 (en) 2009-01-22
ES2379209T3 (es) 2012-04-23
EP2170941A2 (en) 2010-04-07
CN101730711A (zh) 2010-06-09
EP2170941B1 (en) 2011-12-28
AU2008277350B2 (en) 2013-08-22
US8492342B2 (en) 2013-07-23
DK2170941T3 (da) 2012-04-16
JP5393661B2 (ja) 2014-01-22
EP2006384A1 (en) 2008-12-24
ATE539087T1 (de) 2012-01-15
WO2009010874A3 (en) 2009-03-26
AU2008277350A1 (en) 2009-01-22
CA2691406C (en) 2015-11-24
US20100184700A1 (en) 2010-07-22
CA2691406A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
AU749544B2 (en) Tumor antigen peptides originating in cyclophilin B
US8097697B2 (en) Tumor antigen protein SART-3 and tumor antigen peptides thereof
AU762903B2 (en) Mutated peptide compounds, derived from hsp70, useful in cancer immunotherapy
EP4045081A1 (en) Cancer vaccine
CN101730711B (zh) 降钙素原前体抗原t表位
JPWO2000012701A1 (ja) 新規な腫瘍抗原タンパク質ｓａｒｔ−３、およびその腫瘍抗原ペプチド
US7071294B1 (en) Tumor antigen protein art-1 and tumor antigen peptide thereof
EP1103561B1 (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
Hendrickson et al. Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide
JPWO2003008450A1 (ja) 腫瘍抗原
HK1037672A (en) Novel tumor antigen protein sart-3 and tumor antigen peptide thereof
HK1036077A (en) Tumor antigen peptides originating in cyclophilin b

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant